Shilpa Biologicals commissioned a Good Manufacturing Practice (GMP) compliant antibody-drug conjugate (ADC) manufacturing facility, marking a significant step in expanding its biologics manufacturing capabilities. Purpose-built to meet global regulatory standards, the new facility is now fully operational, while GMP qualification protocols are currently in progress. The company stated that the facility has been designed to support the development and manufacturing of
high-quality ADC drug substances for global pharmaceutical and biotechnology companies.
End-to-End ADC Manufacturing Capabilities
With the launch of this facility, Shilpa Biologicals is strengthening its position in the rapidly growing ADC market. Backed by its parent company, Shilpa Medicare, which has invested extensively in highly potent compound manufacturing over the past 25 years, the company now offers a fully integrated ADC development and manufacturing platform.
Its end-to-end capabilities span the entire ADC value chain, including payload synthesis, linker development and manufacturing, monoclonal antibody production, ADC conjugation, and purification of GMP-scale drug substances. This integrated approach enables customers to streamline development timelines while maintaining stringent quality and regulatory standards.
Supporting Global Biopharmaceutical Innovation
The commissioning of the new facility positions Shilpa Biologicals among the few companies in India capable of providing comprehensive ADC drug substance development and manufacturing services under one roof. As demand for targeted cancer therapies continues to rise, the company aims to support global biopharmaceutical innovators with advanced manufacturing infrastructure, technical expertise, and scalable production capabilities. As reported by specchemonline.com, the investment also reinforces Shilpa’s long-term commitment to expanding India’s footprint in the global biologics and oncology manufacturing landscape while catering to the evolving needs of the pharmaceutical industry.
